slides · global inventory
03 Aha Moment
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 2,650
Current window 1,951-1,980
Pages 89
Rows per page 30
Loop
1,951-1,980 of 2,650
29
The slide illustrates the diversity of autoantibodies in myositis patients, supporting the thesis that a broad-acting therapy like Efgartigimod is effective.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
30
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
31
The slide shows 8 individual patient longitudinal plots. Each plot has dual y-axes (CK and Anti-SRP54) and a shared x-axis (Days).argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
32
The chart is a Kaplan-Meier survival curve showing 'DOI-free Survival Probability' over time in weeks.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
33
ProDERM study data comparing IVIg and placebo efficacy over time.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
34
Includes two dot plots showing grip/muscle strength and two microscopy images showing necrosis and complement deposition.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
35
The chart uses a diagonal line to represent growth or accumulation of patient segments.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
36
The slide outlines a clinical trial protocol involving 180 patients, stratified by condition and severity, with a 26-week duration and specific primary/secondary endpoints.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
37
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
38
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
39
The slide uses a structured 4-column layout to summarize the disease profile.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
40
The slide depicts a step-by-step biological pathway (1-6) showing how autoantibodies lead to blister formation. It also highlights the therapeutic target Efgartigimod.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
41
The slide uses a before-after structure to contrast WT mice (susceptible) with FcRn-/- mice (resistant) and shows the impact of HDIG treatment.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
42
The funnel structure implies a progression toward higher selectivity and better outcomes.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
43
The slide presents three distinct clinical datasets (IVIg, Protein A Immunoadsorption, and PLEX) to support the thesis that IgG-targeted therapies lead to fast remissions.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
05
The slide uses a historical analogy to frame the company's mission.Ginkgo | Investor Conference Presentation Deck | 38 slides · Ginkgo Bioworks
Conference presentation Investor relations Beat · Humble OriginsLoop · Aha Moment1 hit
06
The slide uses a split-box layout to distinguish between the founding team and the SPAC partners, with the board listed below.Ginkgo | Investor Conference Presentation Deck | 38 slides · Ginkgo Bioworks
Conference presentation Investor relations Beat · Early StrugglesLoop · Aha Moment1 hit
07
Includes a screenshot from a 60 Minutes segment featuring Ginkgo Bioworks.Ginkgo | Investor Conference Presentation Deck | 38 slides · Ginkgo Bioworks
Conference presentation Investor relations Beat · Early StrugglesLoop · Aha Moment1 hit
08
Uses UN Sustainable Development Goal icons as visual anchors for impact.Ginkgo | Investor Conference Presentation Deck | 38 slides · Ginkgo Bioworks
Conference presentation Investor relations Beat · Early StrugglesLoop · Aha Moment1 hit
09
The slide uses a numbered list format to articulate strategic pillars.Ginkgo | Investor Conference Presentation Deck | 38 slides · Ginkgo Bioworks
Conference presentation Investor relations Beat · Early StrugglesLoop · Aha Moment1 hit
10
The slide uses a numbered list format to present four key strategic pillars.Ginkgo | Investor Conference Presentation Deck | 38 slides · Ginkgo Bioworks
Conference presentation Investor relations Beat · Early StrugglesLoop · Aha Moment1 hit
06
The slide uses a combination of a personal photo (Matt Porteus) and a scientific citation to establish credibility and the 'why now' or 'scientific foundation' of the company.Graphite Bio | IPO Presentation Deck | 50 slides · Graphite Bio
Pitch deck Investment bank Loop · Aha Moment1 hit
07
The slide uses a scientific diagram of the Cas9 mechanism alongside a citation of the seminal 2013 Science paper by Mali et al.Graphite Bio | IPO Presentation Deck | 50 slides · Graphite Bio
Pitch deck Investment bank Loop · Aha Moment1 hit
08
Uses a software UI metaphor ('Find and Replace') to explain biological gene editing.Graphite Bio | IPO Presentation Deck | 50 slides · Graphite Bio
Pitch deck Investment bank Loop · Aha Moment1 hit
09
The slide uses a split-screen comparison layout to contrast two distinct therapeutic modalities.Graphite Bio | IPO Presentation Deck | 50 slides · Graphite Bio
Pitch deck Investment bank Loop · Aha Moment1 hit
19
The slide highlights a specific IP asset (LSD Neutralizer) as a competitive advantage for safety and control.MindMed | Investor Presentation Deck | 33 slides · MindMed
Pitch deck Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
20
The slide outlines the strategic intent of the MindShift partnership to create a new pipeline of drug candidates.MindMed | Investor Presentation Deck | 33 slides · MindMed
Pitch deck Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
21
The slide highlights a specific research initiative led by Dr. Kim Kuypers.MindMed | Investor Presentation Deck | 33 slides · MindMed
Pitch deck Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
04
Includes constant FX adjustments and channel weighting.Salvatore Ferragamo | Results Presentation Deck | 10 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · EvidenceLoop · Aha Moment1 hit
05
Salvatore Ferragamo | Results Presentation Deck | 10 slidesSalvatore Ferragamo | Results Presentation Deck | 10 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · EvidenceLoop · Aha Moment1 hit